4.7 Article

Deciphering metformin action in obese mice: A critical re-evaluation of established protocols

Journal

METABOLISM-CLINICAL AND EXPERIMENTAL
Volume 128, Issue -, Pages -

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.metabol.2021.154956

Keywords

Metformin; Mice; Pharmacokinetics; Glucose

Funding

  1. Austrian Science Fund (FWF) [P30830, P26766]
  2. Austrian Society of Endocrinology and Metabolism
  3. Austrian Science Fund (FWF) [P30830, P26766] Funding Source: Austrian Science Fund (FWF)

Ask authors/readers for more resources

This study investigates the mechanism of metformin in lowering blood glucose, revealing several components including rapid glucose lowering, indirect action via reduced weight gain, and deterioration of glucose homeostasis with prolonged treatment. Previous rodent experiments may have been limited by insufficient consideration of clinical circumstances.
Background and purpose: Despite extensive efforts and a plethora of suggested targets and pathways, the mechanism via which metformin lowers blood glucose remains obscure. Obstacles that hamper progress in understanding metformin action include unexplained discrepancies between preclinical models and patients. Procedures: We treated obese male C57BL/6J mice fed high fat diet with metformin provided in the form of a single dose, daily intraperitoneal injections, admixture to drinking water, or continuous infusion via intraperitoneal minipumps. Results: The results suggest several superimposed components, via which metformin acts on blood glucose. These include (i) marked glucose lowering shortly after dosing, which fades rapidly with the decrease in metformin concentrations in plasma and liver, but could, at least to a major extent, rely on the mechanism also accounting for metformin's therapeutic action in humans; (ii) indirect action via reduced weight gain, which might be responsible for glucose lowering observed in many previous rodent studies; and (iii) deterioration of glucose homeostasis by prolonged treatment that can be unmasked by avoidance of dosing shortly before measuring blood glucose in combination with exclusion of weight-related actions via restricted feeding of the control mice. Conclusions: Our work raises the question whether elucidation of metformin's anti-diabetic mechanism(s) in rodent experiments may in the past have been hampered by failure to mimic clinical circumstances, as caused by insufficient consideration of pharmacokinetics and multiplicity of involved actions. (c) 2021 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available